2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1516

Quality Improvement in Elderly Patients with Rheumatoid Arthritis: Pharmacotherapy and Identification of Cognitive Dysfunction
Abstract Number: 2485

Quality of Evidence of the American College of Rheumatology (ACR) Clinical Practice Guidlines
Abstract Number: 258

Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF
Abstract Number: 2893

Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment
Abstract Number: 694

Quality of Life in Patients with Active Peripheral Spa Is Similarly Impaired As in Other Rheumatic Diseases and Influenced By Disease Activity but Not Disease Duration
Abstract Number: 539

Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
Abstract Number: 1031

Quantifying the Delays to Rheumatologist Consultation and Treatment Among Patients with Systemic Inflammatory Rheumatic Diseases
Abstract Number: 1720

Quantitative Assessment of Bone Marrow Fat Using Magnetic Resonance Imaging in Patients with Spondyloarthropathy
Abstract Number: 2325

Quantitative Clues to Recognize and Document Comorbid Fibromyalgia in Routine Care of Patients with Other Rheumatic Diagnoses on a 10 Cm Distress Visual Analog Scale Found on 1-Page Physician Rheumetric Checklist
Abstract Number: 1314

Quantitative MRI Measurement of Tenosynovitis Demonstrates Differing Responses of Synovitis and Tenosynovitis after RA Treatment
Abstract Number: 375

RA May Not Confer Addition Risk of Osteoporosis in Male Patients – Results of Cohort Analysis and Literature Review
Abstract Number: 457

RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
Abstract Number: 2213

RA-Associated Autoantibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Abstract Number: 528

RA33 Challenges the Paradigm of Autoantigen Selection in Rheumatoid Arthritis
Abstract Number: 484

Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].